Liraglutide Reconstitution Calculator

Yes, in two branded formulations. Victoza (up to 1.8 mg/day) treats type 2 diabetes; Saxenda (3.0 mg/day) is approved for chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related comorbidity (hypertension, dyslipidemia, sleep apnea). Both are FDA/EMA-approved for adolescents ≥12 years with obesity. The ACP ranks liraglutide third-line for obesity, after semaglutide, tirzepatide, and phentermine-topiramate. (guideline/RCT)

No, liraglutide is subcutaneous injection only, regardless of dose or indication. Approved oral GLP-1 options are semaglutide (Rybelsus) and orforglipron, which shows 7.1–10.6% placebo-adjusted weight loss in phase 2/3 trials. Oral liraglutide remains experimental; zein-based nanoparticles matched subcutaneous pharmacokinetics in diabetic rats. If injection is a barrier, choose an approved oral GLP-1 instead (community protocol).

Not in pregnancy, human data are retrospective only, and the ACP guideline requires discussing pregnancy-related factors at initiation. Off-label use in obesity with PCOS is common: one real-world series reported conception after ~10% weight loss and improved menstrual regularity; a dedicated critical review of the PCOS evidence is available. Stop treatment when planning or confirming pregnancy (practitioner consensus).

It is chronic therapy, not a short course. Pivotal RCTs run 26–56 weeks; a real-world 26-week study reported mean −8.5 kg with 76.7% of adults achieving ≥5% weight loss. Assess response after reaching the 3.0 mg daily dose for ~12–16 weeks; discontinue if weight loss is <4–5% (practitioner consensus). Weight regain after stopping is expected. If effective and tolerated, treatment is typically continued long-term.

Liraglutide is the weakest of the three for weight loss. Network meta-analyses show semaglutide and tirzepatide produce the greatest reductions vs placebo; dose-dependent losses are ~8.8–11% (liraglutide 3.0 mg), ~14.9–15.2% (semaglutide 2.4 mg), and 15–18.5% (tirzepatide). Semaglutide also beats liraglutide on cost-effectiveness; liraglutide is generally not cost-effective. Prefer semaglutide or tirzepatide unless cost, availability, or tolerability favor liraglutide.

Unopened pens: store refrigerated at 2–8°C. After first use, pens may be kept up to 30 days at room temperature or refrigerated (product labeling; practitioner consensus). Liraglutide is aggregation-prone: combined air-water and silicone-oil-water interfacial stress triggers fibrillation, and ATR-FTIR detects early degradation. Never freeze; discard if solution is cloudy or contains particles; use an insulated pouch for travel.

Pancreatitis is rare but possible: pooled phase 2/3 trials reported 1.6 vs 0.7 cases/1,000 patient-years versus active comparators; the UK nationwide audit found 0.027/100 patient-years, most with an identifiable cause such as gallstones. Biliary risk is agent-specific: liraglutide was not associated with significant cholelithiasis increases in a large cohort, unlike semaglutide and dulaglutide. Stop and seek care for severe persistent abdominal pain; avoid in patients with prior pancreatitis (practitioner consensus).